

Humber Area Prescribing Committee

Date / Time	7 th December 2022 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – JM to send items approved to Dr Pothina to confirm

Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Simon Priestley- Chief Pharmacist, NLAG (SP) Prof A Morice – Professor of Respiratory Medicine, Chair of D&TC HUTH (AM) Joanne Goode – Chief Pharmacist – HUTH (JG) Daniel Newsome- Principal Pharmacist RDTC (DN) Dr Anupam Sinha- NEL GP Prescribing Lead (AS) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Emma Baggaley, Assistant Director Medicines Management (Superintendent Pharmacist) , CHCP (EB) Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF) Dr Rolan Schreiber, Professional Secretary LMC (RSx)
-------------------	--

Apologies	Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS) Luke Storr – Senior Pharmacy Technician, HUTH Dr Narayana Pothina- Consultant in adult medicine – NLAG (NP) Anna Grocholewska-Mhamdi – Lead Clinical Pharmacist - Navigo
------------------	--

Agenda Number	Item	Discussion	Action	Lead	Due Date
2022.12.01	Apologies	Noted above			
2022.12.02	Declarations of interest	None			
2022.12.03	Minutes of previous meeting	Accepted as true record			
2022.12.04	Action Tracker	<p>Outstanding actions from NLAPC Overactive bladder pathway – JM to contact Mr Gandhi with pathway for agreement in HUTH and to contact ICP team to see if discussed there.</p> <p>Joint formulary Transfer chapter 4 onto netformulary site Chapter 4 done JM to update and complete for next meeting</p> <p>Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies)</p> <p>Ratification of guidelines and SCFs Add type 2 diabetes guidelines as recommendation for discussion at IMOC (action complete)</p> <p>NEW actions To feedback IMOC recommendation to clinicians To feedback to APC when meeting between all services occurred October update – JM to contact Matthew Heppel for timeframes for updated guidance November update – JM to discuss timeframes with Matthew Heppel and ensure gone through local governance process in individual trusts.</p> <p>Action tracker HERPC – Hydroxychloroquine SCF JM to prepare hydrochloroquine SCF</p> <p>Action tracker NLAPC – Triptorelin</p>	<p>JM to chase</p> <p>To check HERPC joint formulary</p> <p>JM&AK to look into for 2023</p> <p>To update next meeting</p> <p>Not till March 23</p> <p>JM sent to AK. Not till March 23</p>	<p>JM</p> <p>JM</p> <p>JM/AK</p> <p>JM</p> <p>JM</p> <p>AK</p>	<p>2/23</p> <p>1/23</p> <p>3/23</p> <p>2/23</p> <p>3/23</p> <p>3/23</p>

	<p>JM/AK to share HERPC guideline with Mr Rogers for transfer into a joint document November update still ongoing Ratification of joint formulary To upload chapter 2 onto joint formulary and remove HERPC chapter 2 when live Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinill and riluzole (joint SCFs) JM to provide RS information on number of patients in NEL/NL Outstanding actions from NLAPC Funding for SCF – Azathioprine/6MP (NEL/N) AK to provide RS information on number of patients in NEL/NL Outstanding actions from NLAPC ADHD shared care (NL) – Awaiting confirmation of funding. Going to next mental health primary/secondary care interface meeting. RS to update when feedback received Outstanding actions from NLAPC Appropriate prescribing of specialist infant formulae – JM to arrange task and finish group for this clinical update Outstanding actions from NLAPC Atomoxetine liquid – SCF ADHD shared care NL awaiting funding (as per other action). NEL within current SCF. Outstanding actions from HERPC Renal repatriation: November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time. Traffic light status To update formulary Ratification of joint formulary To update chapter 13 with update discussed Ratification of joint formulary To upload chapter 13 on netformulary and remove HERPC chapter</p> <p>RTDC updates To update formulary with TAs which were approved AOB JM to send RS details from draft formularies</p>	<p>Ongoing</p> <p>RS not present. Update next meeting</p> <p>RS not present. Update next meeting</p> <p>RS not present. Update next meeting</p> <p>Meeting arranged</p> <p>Awaiting funding</p> <p>Meeting arranged</p> <p>Action complete</p> <p>Action complete</p> <p>Finish Chapter 2 before starting</p> <p>Ongoing</p> <p>JM sent drafts to RS</p>	<p>JM</p> <p>RS</p> <p>RS</p> <p>RS</p> <p>JM</p> <p>RS</p> <p>JM</p> <p>JM/LS</p> <p>JM</p> <p>LS/AK/JM</p> <p>LS/JM/AK</p> <p>JM/RS</p>	<p>3/23</p> <p>1/23</p> <p>1/23</p> <p>1/23</p> <p>2/23</p> <p>1/23</p> <p>1/23</p> <p>12/22</p> <p>12/22</p> <p>4/23</p> <p>1/23</p> <p>1/23</p>
--	--	--	---	---

2022.12.05	Outstanding actions from NLAPC	<ul style="list-style-type: none"> • <i>Prescribing in gestational diabetes</i>- Discussed at business meeting and currently being looked at standardisation of practice across Northern Lincolnshire places- update next meeting 	Ongoing- Awaiting Dr Pothina		
2022.12.06	Outstanding actions from HERPC	<ul style="list-style-type: none"> • Correspondence Received Rheumatology to prepare pathway with rituximab without MTX Awaiting Meeting • Feedback From Commissioning Groups KMc and JM to work with CCG to approve MS guideline JM updated document and sent to Gary Hepworth- document circulated- No responses. JM to confirm with Gary Hepworth next steps. • Hydroxychloroquine SCF JM to discuss ophthalmology checks with rheumatology New action: JM to add Harrogate pathway to agenda when published. New Action: JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning. Escalated and awaiting response from PE&CE • Prescribing guidelines – Dienogest pathway JM to confirm prescribing arrangements with specialist team- Added to hospital systems and formulary • Prescribing guidelines – Renal transplant medicines JM to update with alternative H2 receptor antagonist and review plan for renal repatriation. JM contacted lead renal consultant to discuss to move to HAPC tracker. 	<p>Ongoing</p> <p>To be added to Guideline group</p> <p>Ongoing</p> <p>JM to contact Mrs Allen</p> <p>Moved to HAPC action tracker. Action closed on this tracker</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>1/23</p> <p>1/23</p> <p>1/23</p> <p>1/23</p> <p>12/22</p>
2022.12.07	Traffic Light Status	<p>November 22- HUTH D&T</p> <p>Pirtobrutinib- Approved as RED</p> <p>Icosapent ethyl- Approved as Amber 1</p> <p>Tecovirimat- Approved as RED</p> <p>Itulazax®- Approved as RED</p> <p>Pentazocine- Approved as RED</p> <p>Oraltek- Approved as RED</p>	Update formulary/red list	LS/AK	1/23
2022.12.08	Feedback from Integrated Medicines Optimisation Committee	Feedback around approval of medications and having each area to have approvals (shared care, guidelines and medication) at the same/similar time	Noted		

2022.12.09	Work plans	<ul style="list-style-type: none"> a) Joint formulary alignment b) Shared care frameworks c) Guidelines 	Ongoing for information only		
2022.12.10	Ratification of guidelines and SCFs	<ul style="list-style-type: none"> a) Grazax SCF – JM to look at York classification and discuss classification at formulary subgroup. b) Lithium for cluster headache SCF - Updated SCF based on RMOG SCF, contains same information as current SCF in Hull and ERY. Small number of patients – JM to look at patient numbers. c) Gastrointestinal tract infections for Hull and ER only – updated with new NICE guidance on C difficile. d) Secondary CVD Prevention pathway – this flow chart is part of the lipid guidance and has been updated to include icosopent ethyl. JM to add to document on HAPC site and send link around when done. 	<p>Approved – add to joint formulary agenda</p> <p>Approved – JM to discuss pt numbers with RS</p> <p>To upload on website</p> <p>Approved</p> <p>Approved- JM to upload to current document on HAPC website and e-mail link when complete</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>1/23</p> <p>1/23</p> <p>1/23</p> <p>1/23</p>
2022.12.11	Ratification of joint formulary	Nil this month			
2022.12.12	RTDC updates	<ul style="list-style-type: none"> a) October 22- TA832- No application at HUTH- recommended as AMBER 2 TA833- No ARIA form- proposed as RED. To update formulary with TAs. b) November 22- Monthly horizon scanning report 	Update formulary/red list	JM/LS/AK	1/23
2022.12.13	HAPC Newsletter Template	Presented document. Need to add in Navigo logo in header and change colouring of green drug background. KMc suggested an additional info on formulary chapter updates Discussions about how to distribute the document once re-active and use newsletter to explain the current situation with the transfer from HERPC to HAPC and cascade to all needed. JM to draft a newsletter and send around group for comment	Draft new letter and circulate	JM	1/23
2022.12.14	Minutes from subcommittees	<ul style="list-style-type: none"> a) Joint formulary subcommittee (August 22) b) Guideline subcommittee (July 22) 	Attached for info only		
2022.12.15	Additional minutes for information	<ul style="list-style-type: none"> a) HUTH D&TC (Oct 2022) b) HFT DTG (nil this month) c) NLAG M&T (Oct 2022) d) NYY APC (Oct 2022) 	Attached for info only		
2022.12.16	AOB	Nil			

2022.12.17	Date of next meeting	^{4th} January 13.00 – 15.00 Teams			
-------------------	-----------------------------	--	--	--	--